Saliva HLA as a Marker for MS Treatment Response
Author Information
Author(s): Minagar Alireza, Adamashvili Irena, Kelley Roger E, Gonzalez-Toledo Eduardo, McLarty Jerry, Smith Stacy J
Primary Institution: LSU Health Sciences Center, Shreveport, Louisiana, USA
Hypothesis
Measurement of soluble HLA (sHLA) molecules class II in saliva of MS patients can serve as a marker of therapeutic response to high dose interferon beta-1a.
Conclusion
Serial measurement of saliva sHLA-II may serve as a potential marker of therapeutic response to IFN β-1a.
Supporting Evidence
- The mean saliva sHLA-II levels in MS patients was significantly higher than normal controls.
- Saliva sHLA-II values increased after treatment with IFN β-1a.
- Increases in saliva sHLA-II levels were associated with a stable clinical course.
Takeaway
This study looked at saliva samples from people with multiple sclerosis to see if a certain protein could show how well they respond to treatment. It found that the protein levels went up with treatment, which might mean the treatment is working.
Methodology
Saliva sHLA-II levels were measured in 17 MS patients before and after treatment with interferon beta-1a, compared to 53 normal controls.
Potential Biases
Potential bias due to the limited demographic of participants.
Limitations
The study involved a small sample size and was limited to Caucasian patients.
Participant Demographics
17 Caucasian patients with relapsing/remitting MS, aged approximately 29 years.
Statistical Information
P-Value
p < 0.003 for baseline comparison, p < 0.001 for post-treatment comparisons
Statistical Significance
p < 0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website